NCT04879121 2026-04-16Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid TumorsM.D. Anderson Cancer CenterPhase 2 Recruiting13 enrolled
NCT03155620 2026-04-14Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)National Cancer Institute (NCI)Phase 2 Active not recruiting1,377 enrolled 10 charts
NCT02465060 2026-04-13Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)National Cancer Institute (NCI)Phase 2 Active not recruiting6,452 enrolled 2 FDA
NCT03213704 2025-12-03Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)National Cancer Institute (NCI)Phase 2 Active not recruiting9 enrolled 12 charts
NCT03834961 2025-12-02Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute LeukemiaChildren's Oncology GroupPhase 2 Active not recruiting33 enrolled 18 charts
NCT06390852 2025-11-04Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)National Cancer Institute (NCI)Phase 2 Active not recruiting35 enrolled